Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Now, Moderna will deploy its mRNA technology to research vaccine approaches ... That starting point includes knowledge about viral structure, cell entry and the parts of the virus that might ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

In this article, we are going to look at where Moderna, Inc. (NASDAQ:MRNA) stands against other ... upside potential and an “option-like structure,” particularly when interest rates decline.

The last five years have seen Moderna's (NasdaqGS:MRNA) total shareholder returns ... These lawsuits could affect Moderna's cost structure and product portfolio. Moreover, Moderna's financial ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other stocks with potential to explode in 2025. The recent pullback in US equities can be a sign of ...

Investors in Moderna Inc (Symbol: MRNA) saw new options begin trading this week, for the May 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRNA ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...